

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/713,512	11/14/2000	Nicolaas M.J. Vermeulin	275102001001	4513	
25225	7590 10/22/2002				
MORRISON	& FOERSTER LLP		EXAMI	EXAMINER	
SUITE 500	CENTRE DRIVE		O SULLIVAN, PETER G		
SAN DIEGO,	CA 92130-2332		ART UNIT	PAPER NUMBER	
			1621	(
			DATE MAILED: 10/22/2002	<i>(</i>	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. **09/713,512**

Applicant(s)

Vermeulin et al.

Examiner

Peter O'Sullivan

Art Unit **1621**

	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
Period	for Reply				
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE3 MONTH(S) FROM			
	sions of time may be available under the provisions of 37 CFR 1.136 (a). In g date of this communication,	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
- If the : - If NO : - Failure	operiod for reply specified above is less than thirty (30) days, a reply within th period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause th	and will expire SIX (6) MONTHS from the mailing date of this communication. ne application to become ABANDONED (35 U.S.C. § 133).			
•	eply received by the Office later than three months after the mailing date of t I patent term adjustment. See 37 CFR 1.704(b).	his communication, even if timely filed, may reduce any			
Status					
1) 💢	Responsive to communication(s) filed on Jul 2, 200)2			
2a) 💢	This action is FINAL . 2b) \square This act	ion is non-final.			
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under Ex pair	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposi	tion of Claims				
4) 💢	Claim(s) <u>36-61, 63-77, and 88-95</u>	is/are pending in the application.			
4	la) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 💢	Claim(s) <u>36-61, 63-77, and 88-95</u>	is/are rejected.			
7) 🗌	Claim(s)	is/are objected to.			
· 8) 🗌	Claims	are subject to restriction and/or election requirement.			
Applica	ation Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office action.			
12)	The oath or declaration is objected to by the Exami	ner.			
Priority	under 35 U.S.C. §§ 119 and 120				
13) 🗌	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) 🗆	☐ All b)☐ Some* c)☐ None of:				
	1. \square Certified copies of the priority documents have	e been received.			
	2. \square Certified copies of the priority documents have	e been received in Application No			
	application from the International Burea				
	ee the attached detailed Office action for a list of the	·			
14)∐	Acknowledgement is made of a claim for domestic				
a) L	7				
	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. 33 120 and/or 121.			
Attachm 1) ∏ No	ent(s) stice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
_	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) 🔲 Inf	3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)				

Art Unit: 1621

- 1. Claims 36-61, 63-77 and 88-95 are pending in this application. References not initialed on applicants' form 1449 were not available to the examiner and applicants are requested to send copies with their next response. The rejections under 35 U.S.C. 102(b) and under 35 U.S.C. 112, second paragraph, are withdrawn in view of applicants' arguments and amendments.
- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 4. Claims 36-41, 44-52, 60 and 61 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Cherksey et al. for the reasons of record. Applicants' arguments and declaration have been given due consideration, but are found non-persuasive. Cherksey et al. state, "Illustrative of polyamines useful as such channel regulating agents are the following

Art Unit: 1621

compounds:" of which lysyl spermine is one (s. pg. 19). Applicants provide a showing of beneficial results obtained by using a specific stereoisomeric form, but it is expected that there will be differences in activity of various stereoisomers in biological systems. In re Adamson 125 U.S.P.Q. 233. In re May 197 U.S.P.Q. 601.

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ormum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

6. Claims 36-61, 63-77 and 88-95 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the claims of copending

Application/Control Number: 09/713,512

Page 4

Art Unit: 1621

Application No. 09/396,523. Although the conflicting claims are not identical, they are not patentably distinct from each other because.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

- 7. No claim is allowed.
- 8. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Any inquiry concerning this communication should be directed to Peter O'Sullivan at telephone number (703) 308-4526.

PETER O'SULLIVAN PRIMARY EXAMINES GROUP 1200